Biotechnology Swiss firm Molecular Partners’ shares were up almost 30% at 19.92 Swiss francs by early afternoon, after it a collaboration with pharma giant Novartis in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin program, consisting of two therapeutic candidates, MP0420 and MP0423. 28 October 2020